Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2022 | $28.00 → $5.00 | Buy → Neutral | Goldman |
| 1/13/2022 | $25.00 → $19.00 | Buy | HC Wainwright & Co. |
| 11/19/2021 | $55.00 → $26.00 | Overweight | Piper Sandler |
| 11/10/2021 | $8.00 → $7.00 | Market Perform | SVB Leerink |
| 10/21/2021 | $18.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink |
| 9/20/2021 | $40.00 → $29.00 | Buy | Truist Securities |
| 9/20/2021 | $37.00 → $25.00 | Buy | HC Wainwright & Co. |
| 9/17/2021 | $45.00 → $11.00 | Outperform → Neutral | Wedbush |
15-12G - TCR2 THERAPEUTICS INC. (0001750019) (Filer)
EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)
EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies' complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the w
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2's common stock to one non-executive new hire. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.77, which represents the closing market price
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2's common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.50, which represents the closing mar
Goldman downgraded TCR2 Therapeutics from Buy to Neutral and set a new price target of $5.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $19.00 from $25.00 previously
Piper Sandler resumed coverage of TCR2 Therapeutics with a rating of Overweight and set a new price target of $26.00 from $55.00 previously
4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)
4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)
4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)